Document:

EX-10.2

 Exhibit 10.2 

FORM OF SENIOR SECURED PROMISSORY NOTE 

THE SECURITIES REPRESENTED HEREBY HAVE NOT BEEN REGISTERED UNDER UNITED STATES FEDERAL OR STATE SECURITIES LAWS AND MAY NOT BE OFFERED FOR
SALE, SOLD OR OTHERWISE TRANSFERRED OR ASSIGNED FOR VALUE, DIRECTLY OR INDIRECTLY, NOR MAY THE SECURITIES BE TRANSFERRED ON THE BOOKS OF THE CORPORATION, WITHOUT REGISTRATION OF SUCH SECURITIES UNDER ALL APPLICABLE UNITED STATES FEDERAL OR STATE
SECURITIES LAWS OR COMPLIANCE WITH AN APPLICABLE EXEMPTION THEREFROM, SUCH COMPLIANCE, AT THE OPTION OF THE CORPORATION, TO BE EVIDENCED BY AN OPINION OF SHAREHOLDER’S COUNSEL, IN FORM ACCEPTABLE TO THE CORPORATION, THAT NO VIOLATION OF SUCH
REGISTRATION PROVISIONS WOULD RESULT FROM ANY PROPOSED TRANSFER OR ASSIGNMENT. 
  

					
	April 30, 2014	  		  	$                

 For value received, Bioject Medical Technologies Inc., an Oregon corporation and its wholly owned
subsidiary, Bioject Inc., an Oregon corporation (collectively, the “Debtors”), promise to pay to [insert name] (the “Holder”) the principal sum of [amount in words] and —/100 dollars ($[amount in numbers), together with
interest thereon as set forth herein (this “Note”). 
 The following is a statement of the rights of the Holder and the conditions
to which this Note is subject, and to which the Holder, by the acceptance of this Note, agrees: 
  

	1.	Payment Terms and Security. The unpaid principal balance from time to time outstanding under this Note shall bear interest at the rate of 10% per annum. The outstanding principal balance of and accrued but
unpaid interest under this Note shall be repaid by the Debtors on or before April 30, 2017 (April 30, 2017 or as extended, the “Maturity Date”) unless prepaid or extended pursuant to the terms hereof. Except as otherwise provided
herein, both principal and interest shall be payable on the Maturity Date in lawful money of the United States of America to the Holder at the address listed on the signature page hereto (or at such other location as shall be designated by the
Holder in a written notice to the Debtor), in same day funds. This Note is secured by a pledge of all the intellectual property of the Debtors pursuant to a Security Agreement in the form attached hereto as Annex A. 

 

	2.	Events of Default. If any of the events specified in this Section 2 shall occur (herein individually referred to as an “Event of Default”), the Holder of thisNote may, so long as such condition
exists, declare the entire principal and unpaid accrued interest hereon im’mediately due and payable, without presentment, demand, protest or any other notice of any kind, all of which are hereby expressly waived: 

 

	 	(a)	Default in the payment of the principal and unpaid accrued interest of this Note when due and payable if such default is not cured by the Debtors within ten (10) business days after the Holder has given the
Debtors written notice of such default; or 

  
 Page 1 

	 	(b)	Any breach by the Debtors of any representation, warranty, or covenant in this Note; provided, that, in the event of any such breach, to the extent such breach is 

 

	 	(c)	susceptible to cure, such breach shall not have been cured by the Debtors within ten (10) business days after written notice to the Debtors of such breach; or 

 

	 	(d)	Either Debtor shall (i) apply for or consent to the appointment of a receiver, trustee, liquidator or custodian of itself or of all or a substantial part of its property, (ii) make a general assignment
for the benefit of its or any of its creditors, (iii) be dissolved or liquidated in full or in part, (iv) commence a voluntary case or other proceeding seeking liquidation, reorganization or other relief with respect to itself or its
debts under any bankruptcy, insolvency or other similar law now or hereafter in effect or consent to any such relief or to the appointment of or taking possession of its property by any official in an involuntary case or other proceeding commenced
against it or (v) take any action for the purpose of effecting any of the foregoing; or 

  

	 	(e)	Proceedings for the appointment of a receiver, trustee, liquidator or custodian of either Debtor or of all or a substantial part of the property thereof, or an involuntary case or other proceedings seeking
liquidation, reorganization or other relief with respect to a Debtor or the debts thereof under any bankruptcy, insolvency or other similar law now or hereafter in effect shall be commenced and an order for relief entered, or such case or proceeding
shall not be dismissed, discharged or stayed within 60 days of commencement. 

 Notwithstanding anything to the contrary
contained herein, if any of the events described in Sections 2(c) or (d) occur, this Note shall be automatically accelerated and the entire principal and unpaid accrued interest thereon shall immediately become due and payable without
presentment, demand, protest or any other notice of any kind, all of which are hereby expressly waived. 
  

	3.	Mandatory Prepayment. Prior to the Maturity Date, this Note will be prepaid from 50% of the net proceeds from the sale or licensing of the intellectual property and/or ownership rights of the Debtors, used as
part of a drug device combination; provided however, that such net proceeds must equal or exceed $1,000,000 for such 50% prepayment to be triggered. For the avoidance of doubt and purpose of example, if $1,000,000 in net proceeds are received by the
Debtors, then $500,000 will be used to prepay this Note, subject to the following two sentences. This Note is one of a series of notes, aggregating $2,255,752.61 in principal amount and issued by the Debtors on April 30, 2014. Any prepayments
will be made on a prorated basis among such notes in proportion to the outstanding principal amount of such notes. 

  

	4.	Assignment. The rights and obligations of the Debtors and the Holder of this Note shall be binding upon and benefit the successors, assigns, heirs, administrators and transferees of the parties.

  

	5.	Waiver and Amendment. Any provision of this Note may be amended, waived or modified upon the written consent of the Debtors and the Holder. No waiver by any party of any default, misrepresentation, or breach of
warranty or covenant hereunder, whether intentional or not, shall be deemed to extend to any prior or subsequent default, misrepresentation, or breach of warranty or covenant hereunder or affect in any way any rights arising because of any prior or
subsequent such occurrence. 

  
 Page 2 

	6.	Notices. All notices required or permitted hereunder shall be in writing and shall be deemed effectively given (a) upon personal delivery to the party to be notified, (b) when sent by confirmed telex or
facsimile (provided that notice is also given under clause (c) below) if sent during normal business hours of the recipient; if not sent during normal business hours of the recipient, then on the next business day, or (c) upon receipt by
the party to be notified by nationally recognized overnight courier service. All communications shall be sent to the Debtors at 7180 SW Sandburg Street, Suite 100, Tigard, Oregon 97223 and all communications shall be sent to the Holder at the
address on file with the Debtors. 

  

	7.	Governing Law; Waiver of Jury Trial. This Note shall be governed by and construed in accordance with the laws of the state of Oregon, exclusive of conflicts of law provisions. In the event of any dispute between
the parties to this Note, the parties agree that the dispute shall be settled in the state or federal courts located in the County of Orange in the State of California. The parties hereto waive all right to trial by jury in any action or proceeding
to enforce or defend any rights under this Note. 

  

	8.	Heading; References. All headings used herein are used for convenience only and shall not be used to construe or interpret this Note. Except where otherwise indicated, all references herein to Sections refer to
Sections hereof. 

 IN WITNESS WHEREOF, each of the Debtors has executed this Senior Secured Promissory Note as of the date
first above written. 
  

	
	Bioject Medical Technologies Inc.
	
	  

	By: Mark Logomasini
	President and Chief Executive Officer
	
	Bioject Inc.
	
	  

	By: Mark Logomasini
	President and Chief Executive Officer

  
 Page 3EX-10.3

 Exhibit 10.3 

REGISTRATION RIGHTS AGREEMENT 

This Registration Rights Agreement (the “Agreement”) is made and entered into as of the 30th day of April, 2014 (the “Effective Date”) between Bioject Medical Technologies Inc., an Oregon corporation (the “Company”), and the parties set forth
on the signature page and Exhibit A hereto (each, an “Investor” and collectively, the “Investors”). 

RECITALS 
 A. Certain
Investors have purchased shares of the Company’s Series I Convertible Preferred Stock pursuant to the Company Restructuring Agreement dated April 30, 2014 (the “Restructuring Agreement”) by and between the
Company and each such Investor. 
 B. The Company and certain Investors are parties to a Registration Rights Agreement dated
January 24, 2013, entered into in connection with the sale of the Company’s Series H Preferred Stock (the “Series H Registration Rights Agreement”). 

C. The Company and certain Investors are parties to a Registration Rights Agreement dated December 18, 2009, entered into in connection
with the sale of the Company’s Series G Preferred Stock (the “Series G Registration Rights Agreement”). 
 D.
The Company and certain Investors are parties to a Registration Rights Agreement, dated January 22, 2008, entered into in connection with the sale of the Company’s Series F Preferred Stock (the “Series F Registration Rights
Agreement”). 
 E. The Company and certain Investors are parties to a Securities Purchase Agreement, dated as of March 8,
2006 (the “Series E Purchase Agreement”), Article 6 of which provides registration rights related to the Company’s Series E Preferred Stock and certain warrants (the “Series E Registration Rights
Provisions”). 
 F. The Company and certain Investors are parties to a Registration Rights Agreement, dated November 15,
2004, entered into in connection with the sale of the Company’s Series D Preferred Stock (the “Series D Registration Rights Agreement”). 

G. The Company and the Investors wish to (1) grant registration rights with respect to the Company’s Series I Preferred Stock and
(2) supersede the Series H Registration Rights Agreement, Series G Registration Rights Agreement, the Series F Registration Rights Agreement, Series D Registration Rights Agreement and the Series E Registration Rights Provisions in their
entirety so that all Investors have the same registration rights. 

  
 1 

 NOW, THEREFORE, in consideration of the mutual promises, representations, warranties, covenants,
and conditions set forth herein, the parties mutually agree as follows: 
 AGREEMENT 

1. Certain Definitions. As used in this Agreement, the following terms shall have the following respective meanings: 

“Blackout Period” means, with respect to a registration, a period in each case commencing on the day immediately after the
Company notifies the Investors that they are required, pursuant to Section 4(f) hereof, to suspend offers and sales of Registrable Securities during which the Company, in the good faith judgment of its Board of Directors, determines (because of
the existence of, or in anticipation of, any acquisition, financing activity, or other transaction involving the Company, or the unavailability for reasons beyond the Company’s control of any required financial statements, disclosure of
information which is in its best interest not to publicly disclose, or any other event or condition of similar significance to the Company) that the registration and distribution of the Registrable Securities to be covered by such registration
statement, if any, would be seriously detrimental to the Company and its shareholders and ending on the earlier of (1) the date upon which the material non-public information commencing the Blackout Period is disclosed to the public or ceases
to be material and (2) such time as the Company notifies the selling Holders that the Company will no longer delay such filing of the Registration Statement, recommence taking steps to make such Registration Statement effective, or allow sales
pursuant to such Registration Statement to resume; provided, however, that (a) the Company shall limit its use of Blackout Periods, in the aggregate, to 30 Trading Days in any 12-month period and (b) no Blackout Period may
commence sooner than 60 days after the end of a prior Blackout Period. 
 “Business Day” means any day of the year,
other than a Saturday, Sunday, or other day on which the Commission is required or authorized to close. 
 “Commission”
means the Securities and Exchange Commission or any other federal agency at the time administering the Securities Act. 
 “Common
Stock” means the common stock, no par value, of the Company and any and all shares of capital stock or other equity securities of: (i) the Company which are added to or exchanged or substituted for the Common Stock by reason of the
declaration of any stock dividend or stock split, the issuance of any distribution or the reclassification, readjustment, recapitalization or other such modification of the capital structure of the Company; and (ii) any other corporation, now
or hereafter organized under the laws of any state or other governmental authority, with which the Company is merged, which results from any consolidation or reorganization to which the Company is a party, or to which is sold all or substantially
all of the shares or assets of the Company, if immediately after such merger, consolidation, reorganization or sale, the Company or the stockholders of the Company own equity securities having in the aggregate more than 50% of the total voting power
of such other corporation. 
 “Exchange Act” means the Securities Exchange Act of 1934, as amended, and the rules and
regulations of the Commission promulgated thereunder. 
 “Family Member” means (a) with respect to any individual,
such individual’s spouse, any descendants (whether natural or adopted), any trust all of the beneficial interests of which are owned by any of such individuals or by any of such individuals together with any organization described in
Section 501(c)(3) of the Internal Revenue Code of 1986, as amended, the estate of any such individual, and any corporation, association, partnership or limited liability company all of the equity interests of which are owned by those above
described individuals, trusts or organizations and (b) with respect to any trust, the owners of the beneficial interests of such trust. 

  
 2 

 “Form S-1” means such form under the Securities Act as in effect on the
date hereof or any registration form under the Securities Act subsequently adopted by the Commission to be used instead of a Form S-1. 

“Holder” means each Investor, or any of such Investor’s respective successors and Permitted Assigns who acquire rights
in accordance with this Agreement with respect to the Registrable Securities directly or indirectly from an Investor, including from any Permitted Assignee. 

“Inspector” means any attorney, accountant, or other agent retained by an Investor for the purposes provided in
Section 4(j). 
 “Majority Holders” means at any time Holders of a majority of the Registrable Securities. 

“Permitted Assignee” means (a) with respect to a partnership, its partners or former partners in accordance with their
partnership interests, (b) with respect to a corporation, its shareholders in accordance with their interest in the corporation, (c) with respect to a limited liability company, its members or former members in accordance with their
interest in the limited liability company, (d) with respect to an individual party, any Family Member of such party, (e) an entity that is controlled by, controls, or is under common control with a transferor, or (f) a party to this
Agreement. 
 “Preferred Stock” means the Series D Preferred Stock, Series E Preferred Stock, Series F
Preferred Stock, Series G Preferred Stock, Series H Preferred Stock and Series I Preferred Stock of the Company. 
 The terms
“register,” “registered,” and “registration” refer to a registration affected by preparing and filing a registration statement in compliance with the Securities Act, and the declaration or ordering
of the effectiveness of such registration statement. 
 “Registrable Securities” means shares of Common Stock issued
or issuable to each Investor upon conversion of the Preferred Stock issued to each, excluding (i) any Registrable Securities that have been publicly sold or may be sold immediately without registration under the Securities Act either
pursuant to Rule 144 of the Securities Act or otherwise; (ii) any Registrable Securities sold by a person in a transaction pursuant to a registration statement filed under the Securities Act or (iii) any Registrable Securities that
are at the time subject to an effective registration statement under the Securities Act. 
 “Registration Statement” means
the registration statement required to be filed by the Company pursuant to Section 3(a). 
 “Securities Act” means the
Securities Act of 1933, as amended, or any similar federal statute promulgated in replacement thereof, and the rules and regulations of the Commission thereunder, all as the same shall be in effect at the time. 

“SEC Effective Date” means the date the Registration Statement is declared effective by the Commission. 

“Trading Day” means a day on whichever (a) the national securities exchange, (b) the Nasdaq Capital Market, or
(c) such other securities market, in any such case which at the time constitutes the principal securities market for the Common Stock, is open for general trading of securities. 

  
 3 

 2. Term. This Agreement shall continue in full force and effect for a period of eight
(8) years from the Effective Date. 
 3. Registration. 

(a) Registration on Form S-1. As promptly as reasonably practicable after the date on which the Majority Holders request in
writing (the “Demand Date”), but in any event not later than 180 days after such date ( the “Registration Filing Date”), the Company shall use its commercially reasonable efforts to file with the
Commission a registration statement on Form S-1 relating to the resale by the Holders of all of the Registrable Securities; provided, however, that the Company shall not be obligated to effect any such registration, qualification,
or compliance pursuant to this Section 3(a), or keep such registration effective pursuant to Section 4: (i) in any particular jurisdiction in which the Company would be required to qualify to do business as a foreign corporation or as
a dealer in securities under the securities or blue sky laws of such jurisdiction or to execute a general consent to service of process in effecting such registration, qualification or compliance, in each case where it has not already done so; or
(ii) during any Blackout Period, in which case the Registration Filing Date shall be extended to the date immediately following the last day of such Blackout Period. 

(b) Piggyback Registration. If the Company shall determine to register for sale for cash any of its Common Stock, for its own account
or for the account of others (other than the Holders) pursuant to the exercise of demand registration rights, other than (i) a registration relating solely to employee benefit plans or securities issued or issuable to employees, consultants (to
the extent the securities owned or to be owned by such consultants could be registered on Form S-8) or any of their Family Members (including a registration on Form S-8) or (ii) a registration relating solely to a Commission
Rule 145 transaction, a registration on Form S-4 in connection with a merger, acquisition, divestiture, reorganization, or similar event, the Company shall promptly give to the Holders written notice thereof (and in no event shall such
notice be given less than 20 calendar days prior to the filing of such registration statement), and shall, subject to Section 3(c), include in such registration (and any related qualification under blue sky laws or other compliance) (a
“Piggyback Registration”), all of the Registrable Securities specified in a written request or requests, made within 10 calendar days after receipt of such written notice from the Company, by any Holder or Holders. However,
the Company may, without the consent of the Holders, withdraw such registration statement prior to its becoming effective if the Company or such other shareholders have elected to abandon the proposal to register the securities proposed to be
registered thereby. 
 (c) Underwriting. If a Piggyback Registration is for a registered public offering involving an underwriting,
the Company shall so advise the Holders in writing or as a part of the written notice given pursuant to Section 3(b). In such event the right of any Holder to registration pursuant to Section 3(b) shall be conditioned upon such
Holder’s participation in such underwriting and the inclusion of such Holder’s Registrable Securities in the underwriting to the extent provided herein. All Holders proposing to distribute their securities through such underwriting shall
(together with the Company and any other shareholders of the Company distributing their securities through such underwriting) enter into an underwriting agreement in 

  
 4 

 
customary form with the underwriter or underwriters selected for such underwriting by the Company or selling shareholders, as applicable. Notwithstanding any other provision of this
Section 3(c), if the underwriter or the Company determines that marketing factors require a limitation of the number of shares to be underwritten, the underwriter may exclude some or all Registrable Securities from such registration and
underwriting. The Company shall so advise all Holders (except those Holders who failed to timely elect to distribute their Registrable Securities through such underwriting or have indicated to the Company their decision not to do so), and the number
of shares of Registrable Securities that may be included in the registration and underwriting, if any, shall be allocated among such Holders as follows: 

(i) In the event of a Piggyback Registration that is initiated by the Company, the number of shares that may be included in the registration
and underwriting shall be allocated first to the Company and then, subject to obligations and commitments existing as of the date hereof, to all selling shareholders, including the Holders, who have requested to sell in the registration on a pro
rata basis according to the number of shares requested to be included; and 
 (ii) In the event of a Piggyback Registration that is
initiated by the exercise of demand registration rights by a shareholder or shareholders of the Company (other than the Holders), then the number of shares that may be included in the registration and underwriting shall be allocated first to such
selling shareholders who exercised such demand and then, subject to obligations and commitments to all other selling shareholders, including the Holders, who have requested to sell in the registration, on a pro rata basis according to the number of
shares requested to be included. 
 No Registrable Securities excluded from the underwriting by reason of the underwriter’s marketing
limitation shall be included in such registration. If any Holder disapproves of the terms of any such underwriting, such Holder may elect to withdraw therefrom by written notice to the Company and the underwriter. The Registrable Securities and/or
other securities so withdrawn from such underwriting shall also be withdrawn from such registration; provided, however, that, if by the withdrawal of such Registrable Securities a greater number of Registrable Securities held by other
Holders may be included in such registration (up to the maximum of any limitation imposed by the underwriters), then the Company shall offer to all Holders who have included Registrable Securities in the registration the right to include additional
Registrable Securities pursuant to the terms and limitations set forth herein in the same proportion used above in determining the underwriter limitation. 

(d) Other Registrations. Prior to the SEC Effective Date the Company will not, without the prior written consent of the Majority
Holders, file or request the acceleration of any other registration statement filed with the Commission, and during any time subsequent to the SEC Effective Date when the Registration Statement for any reason is not available for use by any Holder
for the resale of any Registrable Securities, the Company shall not, without the prior written consent of the Majority Holders, file any other registration statement or any amendment thereto with the Commission under the Securities Act or request
the acceleration of the effectiveness of any other registration statement previously filed with the Commission, other than (A) any registration statement on Form S-8 or Form S-4 and (B) any registration statement or amendment
which the Company is required to file or as to which the Company is required to request acceleration pursuant to any obligation in effect on the date of execution and delivery of this Agreement. 

  
 5 

 4. Registration Procedures. In the case of each registration, qualification, or compliance
effected by the Company pursuant to Section 3 hereof, the Company will keep each Holder including securities therein reasonably advised in writing (which may include e-mail) as to the initiation of each registration, qualification, and
compliance and as to the completion thereof. At its expense with respect to any registration statement filed pursuant to Section 3, the Company will use its commercially reasonable efforts to: 

(a) prepare and file with the Commission with respect to such Registrable Securities, a registration statement on Form S-1 or any other
form for which the Company then qualifies or which counsel for the Company shall deem appropriate, and which form shall be available for the sale of the Registrable Securities in accordance with the intended method(s) of distribution thereof,
and use its commercially reasonable efforts to cause such registration statement to become and remain effective at least for a period ending with the first to occur of (i) the sale of all Registrable Securities covered by the registration
statement, and (ii) the availability under Rule 144 for the Holder to immediately, freely resell without restriction all Registrable Securities covered by the registration statement (in either case, the “Effectiveness
Period”); provided that no later than two business days before filing with the Commission a registration statement or prospectus or any amendments or supplements thereto, the Company shall (i) furnish to one special counsel
(“Holders’ Counsel”) selected by the Majority Holders for the benefit of the Holders, copies of all such documents proposed to be filed (excluding any exhibits other than applicable underwriting documents), in
substantially the form proposed to be filed, which documents shall be subject to the review of such Holders’ Counsel, and (ii) notify each Holder of Registrable Securities covered by such registration statement of any stop order issued or
threatened by the Commission and take all reasonable actions required to prevent the entry of such stop order or to remove it if entered; 

(b) if a registration statement is subject to review by the Commission, promptly respond to all comments and diligently pursue resolution of
any comments to the satisfaction of the Commission; 
 (c) prepare and file with the Commission such amendments and supplements to such
registration statement and the prospectus used in connection therewith as may be necessary to keep such registration statement effective during the Effectiveness Period (but in any event at least until expiration of the 90-day period referred to in
Section 4(3) of the Securities Act and Rule 174, or any successor thereto, thereunder, if applicable), and comply with the provisions of the Securities Act with respect to the disposition of all securities covered by such registration
statement during such period in accordance with the intended method(s) of disposition by the sellers thereof set forth in such registration statement; 

(d) furnish, without charge, to each Holder of Registrable Securities covered by such registration statement (i) a reasonable number of
copies of such registration statement (including any exhibits thereto other than exhibits incorporated by reference), each amendment and supplement thereto as such Holder may request, (ii) such number of copies of the prospectus included in
such registration statement (including each preliminary prospectus and any other prospectus filed under Rule 424 under the Securities Act) as such Holders may request, in conformity with the requirements of the Securities Act, and
(iii) such other documents as such Holder may reasonably request in order to facilitate the disposition of the Registrable Securities owned by such Holder, but only during the Effectiveness Period; 

  
 6 

 (e) use its commercially reasonable efforts to register or qualify such Registrable Securities
under such other applicable securities or blue sky laws of such jurisdictions as any Holder of Registrable Securities covered by such registration statement reasonably requests as may be necessary for the marketability of the Registrable Securities
(such request to be made by the time the applicable registration statement is deemed effective by the Commission) and do any and all other acts and things which may be reasonably necessary or advisable to enable such Holder to consummate the
disposition in such jurisdictions of the Registrable Securities owned by such Holder; provided that the Company shall not be required to (i) qualify generally to do business in any jurisdiction where it would not otherwise be required to
qualify but for this paragraph (e), (ii) subject itself to taxation in any such jurisdiction, or (iii) consent to general service of process in any such jurisdiction; 

(f) as promptly as practicable after becoming aware of such event, notify each Holder of such Registrable Securities at any time when a
prospectus relating thereto is required to be delivered under the Securities Act of the happening of any event which comes to the Company’s attention if as a result of such event the prospectus included in such registration statement contains
an untrue statement of a material fact or omits to state any material fact required to be stated therein or necessary to make the statements therein not misleading and the Company shall promptly prepare and furnish to such Holder a supplement or
amendment to such prospectus (or prepare and file appropriate reports under the Exchange Act) so that, as thereafter delivered to the purchasers of such Registrable Securities, such prospectus shall not contain an untrue statement of a material fact
or omit to state any material fact required to be stated therein or necessary to make the statements therein not misleading, unless suspension of the use of such prospectus otherwise is authorized herein or in the event of a Blackout Period, in
which case no supplement or amendment need be furnished (or Exchange Act filing made) until the termination of such suspension or Blackout Period; 

(g) comply, and continue to comply during the period that such registration statement is effective under the Securities Act, in all material
respects with the Securities Act and the Exchange Act and with all applicable rules and regulations of the Commission with respect to the disposition of all securities covered by such registration statement; 

(h) as promptly as practicable after becoming aware of such event, notify each Holder of Registrable Securities being offered or sold pursuant
to the Registration Statement of the issuance by the Commission of any stop order or other suspension of effectiveness of the Registration Statement at the earliest possible time; 

(i) permit the Holders of Registrable Securities being included in the Registration Statement and their legal counsel, at such Holders’
sole cost and expense (except as otherwise specifically provided in Section 6) to review and have a reasonable opportunity to comment on the Registration Statement and all amendments and supplements thereto at least two Business Days prior
to their filing with the Commission and shall not file any such document to which the Majority Holders reasonably object; 
 (j) make
available for inspection by any Holder and any Inspector retained by such Holder, at such Holder’s sole expense, all Records as shall be reasonably necessary to enable such Holder to exercise its due diligence responsibility, and cause the
Company’s officers, directors, and employees to supply all information which such Holder or any Inspector may 

  
 7 

 
reasonably request for purposes of such due diligence; provided, however, that such Holder shall hold in confidence and shall not make any disclosure of any record or other information which the
Company determines in good faith to be confidential, and of which determination such Holder is so notified at the time such Holder receives such information, unless (i) the disclosure of such record is necessary to avoid or correct a
misstatement or omission in the Registration Statement and a reasonable time prior to such disclosure the Holder shall have informed the Company of the need to so correct such misstatement or omission and the Company shall have failed to correct
such misstatement of omission, (ii) the release of such record is ordered pursuant to a subpoena or other order from a court or governmental body of competent jurisdiction or (iii) the information in such record has been made generally
available to the public other than by disclosure in violation of this or any other agreement. The Company shall not be required to disclose any confidential information in such records to any Inspector until and unless such Inspector shall have
entered into a confidentiality agreement with the Company with respect thereto, substantially in the form of this Section 4(j), which agreement shall permit such Inspector to disclose records to the Holder who has retained such Inspector. Each
Holder agrees that it shall, upon learning that disclosure of such Records is sought in or by a court or governmental body of competent jurisdiction or through other means, give prompt notice to the Company and allow the Company, at the
Company’s expense, to undertake appropriate action to prevent disclosure of, or to obtain a protective order for, the records deemed confidential. The Company shall hold in confidence and shall not make any disclosure of information concerning
a Holder provided to the Company pursuant to this Agreement unless (i) disclosure of such information is necessary to comply with federal or state securities laws, (ii) disclosure of such information to the Staff of the Division of
Corporation Finance is necessary to respond to comments raised by the Staff in its review of the Registration Statement, (iii) disclosure of such information is necessary to avoid or correct a misstatement or omission in the Registration
Statement, (iv) release of such information is ordered pursuant to a subpoena or other order from a court or governmental body of competent jurisdiction, or (v) such information has been made generally available to the public other than by
disclosure in violation of this or any other agreement. The Company agrees that it shall, upon learning that disclosure of such information concerning a Holder is sought in or by a court or governmental body of competent jurisdiction or through
other means, give prompt notice to such Holder and allow such Holder, at such Holder’s expense, to undertake appropriate action to prevent disclosure of, or to obtain a protective order for, such information; 

(k) use its commercially reasonable efforts to cause all the Registrable Securities covered by the Registration Statement to be quoted on the
principal securities market on which securities of the same class or series issued by the Company are then listed or traded; 
 (l) provide
a transfer agent and registrar, which may be a single entity, for the Registrable Securities at all times; 
 (m) cooperate with the Holders
of Registrable Securities being offered pursuant to the Registration Statement to facilitate the timely preparation and delivery of certificates (not bearing any restrictive legends) representing Registrable Securities sold pursuant to the
Registration Statement and enable such certificates to be in such denominations or amounts as the Holders may reasonably request and registered in such names as the Holders may request; 

  
 8 

 (n) during the Effectiveness Period, refrain from bidding for or purchasing any Common Stock or
any right to purchase Common Stock or attempting to induce any Person to purchase any such security or right if such bid, purchase or attempt would in any way limit the right of the Holders to sell Registrable Securities by reason of the limitations
set forth in Regulation M under the 1934 Act; and 
 (o) take all other reasonable actions necessary to expedite and facilitate disposition
by the Holders of the Registrable Securities pursuant to the Registration Statement. 
 5. Suspension of Offers and Sales. Each
Holder of Registrable Securities agrees that, upon receipt of any notice from the Company of the happening of any event of the kind described in Section 4(f) hereof or of the commencement of a Blackout Period, such Holder shall discontinue
disposition of Registrable Securities pursuant to the registration statement covering such Registrable Securities until such Holder’s receipt of the copies of the supplemented or amended prospectus contemplated by Section 4(f) hereof
or notice of the end of the Blackout Period, and, if so directed by the Company, such Holder shall deliver to the Company (at the Company’s expense) all copies (including, without limitation, any and all drafts), other than permanent file
copies, then in such Holder’s possession, of the prospectus covering such Registrable Securities current at the time of receipt of such notice. In the event the Company shall give any such notice, the period mentioned in
Section 4(a)(iii) hereof shall be extended by the greater of (i) ten business days or (ii) the number of days during the period from and including the date of the giving of such notice pursuant to Section 4(f) hereof to
and including the date when each Holder of Registrable Securities covered by such registration statement shall have received the copies of the supplemented or amended prospectus contemplated by Section 4(f) hereof. 

6. Registration Expenses. The Company shall pay all expenses in connection with any registration, including, without limitation, all
registration, filing, stock exchange fees, printing expenses, all fees and expenses of complying with securities or blue sky laws, the fees and disbursements of counsel for the Company and of its independent accountants, and the reasonable fees and
disbursements of a Holders’ Counsel (not to exceed $10,000); provided that, in any underwritten registration, each party shall pay for its own underwriting discounts and commissions and transfer taxes. Except as provided above in this
Section 6 and Section 9, the Company shall not be responsible for the expenses of any attorney or other advisor employed by a Holder of Registrable Securities. 

7. Assignment of Rights. No Holder may assign its rights under this Agreement to any party without the prior written consent of the
Company; provided, however, that a Holder may assign its rights under this Agreement without such restrictions to a Permitted Assignee as long as (a) such transfer or assignment is effected in accordance with applicable securities
laws; (b) such transferee or assignee agrees in writing to become subject to the terms of this Agreement; and (c) the Company is given written notice by such Holder of such transfer or assignment, stating the name and address of the
transferee or assignee and identifying the Registrable Securities with respect to which such rights are being transferred or assigned. 
 8.
Information by Holder. The Holder or Holders of Registrable Securities included in any registration shall furnish to the Company such information regarding such Holder or Holders and the distribution proposed by such Holder or Holders as the
Company may request in writing. 

  
 9 

 9. Indemnification. 

(a) In the event of the offer and sale of Registrable Securities held by Holders under the Securities Act, the Company shall, and hereby does,
indemnify and hold harmless, to the fullest extent permitted by law, each Holder, its directors, officers, partners, and each other person, if any, who controls or is under common control with such Holder or any such underwriter within the meaning
of Section 15 of the Securities Act, against any losses, claims, damages or liabilities, joint or several, and expenses to which the Holder or any such director, officer, partner or underwriter or controlling person may become subject under the
Securities Act or otherwise, insofar as such losses, claims, damages, liabilities or expenses (or actions or proceedings, whether commenced or threatened, in respect thereof) arise out of or are based upon any untrue statement or alleged untrue
statement of any material fact contained in any registration statement under which such shares were registered under the Securities Act, any preliminary prospectus, final prospectus or summary prospectus contained therein, or any amendment or
supplement thereto, or any omission or alleged omission to state therein a material fact required to be stated therein or necessary to make the statements therein in light of the circumstances in which they were made not misleading, and the Company
shall reimburse the Holder, and each such director, officer, partner, and controlling person for any legal or any other expenses reasonably incurred by them in connection with investigating, defending or settling any such loss, claim, damage,
liability, action or proceeding; provided that the Company shall not be liable in any such case (i) to the extent that any such loss, claim, damage, liability (or action or proceeding in respect thereof) or expense arises out of or is based
upon an untrue statement or alleged untrue statement in or omission or alleged omission from such registration statement, any such preliminary prospectus, final prospectus, summary prospectus, amendment or supplement in reliance upon and in
conformity with written information furnished to the Company by or on behalf of such Holder or (ii) if the person asserting any such loss, claim, damage, liability (or action or proceeding in respect thereof) who purchased the Registrable
Securities that are the subject thereof did not receive a copy of an amended preliminary prospectus or the final prospectus (or the final prospectus as amended or supplemented) at or prior to the written confirmation of the sale of such Registrable
Securities to such person because of the failure of such Holder or underwriter to so provide such amended preliminary or final prospectus and the untrue statement or alleged untrue statement or omission or alleged omission of a material fact made in
such preliminary prospectus was corrected in the amended preliminary or final prospectus (or the final prospectus as amended or supplemented). Such indemnity shall remain in full force and effect regardless of any investigation made by or on behalf
of the Holders, or any such director, officer, partner, underwriter or controlling person and shall survive the transfer of such shares by the Holder. 

(b) As a condition to including any Registrable Securities to be offered by a Holder in any registration statement filed pursuant to this
Agreement, each such Holder agrees to be bound by the terms of this Section 9 and to indemnify and hold harmless, to the fullest extent permitted by law, the Company, its directors and officers, and each other person, if any, who controls the
Company within the meaning of Section 15 of the Securities Act, against any losses, claims, damages or liabilities, joint or several, to which the Company or any such director or officer or controlling person may become subject under the
Securities Act or otherwise, insofar as such losses, claims, damages or liabilities (or actions or proceedings, whether commenced or threatened, in respect thereof) arise out of or are based upon any untrue statement or alleged

  
 10 

 
untrue statement in or omission or alleged omission from such registration statement, any preliminary prospectus, final prospectus or summary prospectus contained therein, or any amendment or
supplement thereto, if such statement or alleged statement or omission or alleged omission was made in reliance upon and in conformity with written information about such Holder as a Holder of the Company furnished to the Company, and such Holder
shall reimburse the Company, and each such director, officer, and controlling person for any legal or other expenses reasonably incurred by them in connection with investigating, defending, or settling any such loss, claim, damage, liability,
action, or proceeding; provided, however, that such indemnity agreement found in this Section 9(b) shall in no event exceed the gross proceeds from the offering received by such Holder. Such indemnity shall remain in full
force and effect, regardless of any investigation made by or on behalf of the Company or any such director, officer or controlling person and shall survive the transfer by any Holder of such shares. 

(c) Promptly after receipt by an indemnified party of notice of the commencement of any action or proceeding involving a claim referred to in
Section 9(a) or (b) hereof (including any governmental action), such indemnified party shall, if a claim in respect thereof is to be made against an indemnifying party, give written notice to the indemnifying party of the commencement
of such action; provided that the failure of any indemnified party to give notice as provided herein shall not relieve the indemnifying party of its obligations under Section 9(a) or (b) hereof, except to the extent that the
indemnifying party is actually prejudiced by such failure to give notice. In case any such action is brought against an indemnified party, unless in the reasonable judgment of counsel to such indemnified party a conflict of interest between such
indemnified and indemnifying parties may exist or the indemnified party may have defenses not available to the indemnifying party in respect of such claim, the indemnifying party shall be entitled to participate in and to assume the defense thereof,
with counsel reasonably satisfactory to such indemnified party and, after notice from the indemnifying party to such indemnified party of its election so to assume the defense thereof, the indemnifying party shall not be liable to such indemnified
party for any legal or other expenses subsequently incurred by the latter in connection with the defense thereof, unless in such indemnified party’s reasonable judgment a conflict of interest between such indemnified and indemnifying parties
arises in respect of such claim after the assumption of the defenses thereof or the indemnifying party fails to defend such claim in a diligent manner, other than reasonable costs of investigation. Neither an indemnified nor an indemnifying party
shall be liable for any settlement of any action or proceeding affected without its consent. No indemnifying party shall, without the consent of the indemnified party, consent to entry of any judgment or enter into any settlement, which does not
include as an unconditional term thereof the giving by the claimant or plaintiff to such indemnified party of a release from all liability in respect of such claim or litigation. Notwithstanding anything to the contrary set forth herein, and without
limiting any of the rights set forth above, in any event any party shall have the right to retain, at its own expense, counsel with respect to the defense of a claim. 

(d) In the event that an indemnifying party does not or is not permitted to assume the defense of an action pursuant to
Section 9(c) or in the case of the expense reimbursement obligation set forth in Section 9(a) and (b), the indemnification required by Section 9(a) and (b) hereof shall be made by periodic payments of the amount
thereof during the course of the investigation or defense, as and when bills received or expenses, losses, damages, or liabilities are incurred. 

  
 11 

 (e) If the indemnification provided for in this Section 9 is held by a court of competent
jurisdiction to be unavailable to an indemnified party with respect to any loss, liability, claim, damage or expense referred to herein, the indemnifying party, in lieu of indemnifying such indemnified party hereunder, shall (i) contribute to
the amount paid or payable by such indemnified party as a result of such loss, liability, claim, damage or expense as is appropriate to reflect the proportionate relative fault of the indemnifying party on the one hand and the indemnified party on
the other (determined by reference to, among other things, whether the untrue or alleged untrue statement of a material fact or omission relates to information supplied by the indemnifying party or the indemnified party and the parties’
relative intent, knowledge, access to information and opportunity to correct or prevent such untrue statement or omission), or (ii) if the allocation provided by clause (i) above is not permitted by applicable law or provides a lesser sum
to the indemnified party than the amount hereinafter calculated, not only the proportionate relative fault of the indemnifying party and the indemnified party, but also the relative benefits received by the indemnifying party on the one hand and the
indemnified party on the other, as well as any other relevant equitable considerations. No indemnified party guilty of fraudulent misrepresentation (within the meaning of Section 11(f) of the Securities Act) shall be entitled to
contribution from any indemnifying party who was not guilty of such fraudulent misrepresentation. 
 (f) Other Indemnification.
Indemnification similar to that specified in the preceding subsections of this Section 9 (with appropriate modifications) shall be given by the Company and each Holder of Registrable Securities with respect to any required registration or other
qualification of securities under any federal or state law or regulation or governmental authority other than the Securities Act. 
 10.
Miscellaneous. 
 (a) Governing Law. This Agreement shall be governed by and construed in accordance with the laws of the
State of Oregon and the United States of America, both substantive and remedial. Any judicial proceeding brought against either of the parties to this agreement or any dispute arising out of this Agreement or any matter related hereto may be brought
in the courts of the State of Oregon or in the United States District Court for the District of Oregon and, by its execution and delivery of this agreement, each party to this Agreement accepts the jurisdiction of such courts. The foregoing consent
to jurisdiction shall not be deemed to confer rights on any person other than the parties to this Agreement. 
 (b) Successors and
Assigns. Except as otherwise provided herein, the provisions hereof shall inure to the benefit of, and be binding upon, the successors, Permitted Assigns, executors and administrators of the parties hereto. In the event the Company merges with,
or is otherwise acquired by, a direct or indirect subsidiary of a publicly traded company, the Company shall condition the merger or acquisition on the assumption by such parent company of the Company’s obligations under this Agreement. 

(c) Entire Agreement. This Agreement constitutes the full and entire understanding and agreement between the parties with regard to the
subjects hereof and amends and supersedes in their entirety the Series E Registration Rights Provisions, the Series D Registration Rights Agreement, the Series F Registration Rights Agreement, the Series G Registration Rights Agreement and the
Series H Registration Rights Agreement. 

  
 12 

 (d) Notices, etc. All notices or other communications which are required or permitted
under this Agreement shall be in writing and sufficient if delivered by hand, by facsimile transmission, by registered or certified mail, postage pre-paid, by electronic mail, or by courier or overnight carrier, to the persons at the addresses set
forth below (or at such other address as may be provided hereunder), and shall be deemed to have been delivered as of the date so delivered: 
  

			
	If to the Company:	  	 Bioject Medical Technologies Inc.
 7180 SW
Sandburg Street, Suite 100
 Tigard, OR 97223
 Attention: Chief
Executive Officer
 Facsimile: (503) 692-6698
 E-mail:
mlogomasini@bioject.com

		
	If to the Investors:	  	 To each Investor
 at the address on file with
the Company

 or at such other address as any party shall have furnished to the other parties in writing. 

(e) Delays or Omissions. No delay or omission to exercise any right, power or remedy accruing to any Holder of any Registrable
Securities, upon any breach or default of the Company under this Agreement, shall impair any such right, power or remedy of such Holder nor shall it be construed to be a waiver of any such breach or default, or an acquiescence therein, or of or in
any similar breach or default thereunder occurring; nor shall any waiver of any single breach or default be deemed a waiver of any other breach or default theretofore or thereafter occurring. Any waiver, permit, consent or approval of any kind or
character on the part of any Holder of any breach or default under this Agreement, or any waiver on the part of any Holder of any provisions or conditions of this Agreement, must be in writing and shall be effective only to the extent specifically
set forth in such writing. All remedies, either under this Agreement, or by law or otherwise afforded to any holder, shall be cumulative and not alternative. 

(f) Counterparts. This Agreement may be executed in any number of counterparts, each of which shall be enforceable against the parties
actually executing such counterparts, and all of which together shall constitute one instrument. 
 (g) Severability. In the case any
provision of this Agreement shall be invalid, illegal or unenforceable, the validity, legality and enforceability of the remaining provisions shall not in any way be affected or impaired thereby. 

(h) Amendments. The provisions of this Agreement may be amended at any time and from time to time, and particular provisions of this
Agreement may be waived, with and only with an agreement or consent in writing signed by the Company and by the holders of 80% of the number of shares of Registrable Securities outstanding as of the date of such amendment or waiver. The Investors
acknowledge that by the operation of this Section 10(h), the holders of 80% of the outstanding Registrable Securities may have the right and power to diminish or eliminate all rights of the Investors under this Agreement. If prior to the
expiration or termination of this Agreement the Company becomes eligible to use a shelf registration statement with respect to the resale of the Registrable Securities on Form S-3 or any future form that permits

  
 13 

 
continuous incorporation by reference of the Company’s filings under the Exchange Act, the parties agree to amend this Agreement to add provisions similar to those in Section 3(a) of
the Series F Registration Rights Agreement. 
 (i) Limitation on Subsequent Registration Rights. After the date of this Agreement,
the Company shall not, without the prior written consent of the Holders of at least a majority of the Registrable Securities then outstanding, enter into any agreement with any holder or prospective holder of any securities of the Company that would
grant such holder registration rights senior to those granted to the Holders hereunder. 
 This Registration Rights Agreement is hereby executed as of the
date first above written. 
  

			
	 Bioject Medical Technologies Inc.

	
	 /s/ Mark Logomasini

	 By: Mark Logomasini

	 President and Chief Executive Officer

	
	 Life Sciences Opportunities Fund II, L.P.

	 By Signet Healthcare Partners, LLC

		
	By:	 	 /s/ James Gale

	 James Gale

	 Managing Director

	
	 Life Sciences Opportunities Fund II (Institutional), L.P.

	 By Signet Healthcare Partners, LLC

		
	By:	 	 /s/ James Gale

	 James Gale

	 Managing Director

	
	 Edward Flynn

	
	 /s/ Edward Flynn

  
 14 

	
	Mark A. Logomasini & Associates Inc. SEP Fund
	
	 /s/ Mark Logomasini

	
	Richard Richieri
	
	 /s/ Richard Richieri

	
	Albert Hansen
	 /s/ Albert Hansen

  
 15 

 EXHIBIT A 

INVESTOR INFORMATION 
  

	1.	Life Sciences Opportunities Fund II, L.P. 

 11,388 shares of Series H Preferred Stock

 4,135 shares of Series I Preferred Stock 

2,539,627 shares of Common Stock 
  

	2.	Life Sciences Opportunities Fund II (Institutional), L.P. 

 63,612 shares of Series H
Preferred Stock 
 23,095 shares of Series I Preferred Stock 

14,296,185 shares of Common Stock 
  

	3.	Sanders Opportunity Fund, L.P. 

 207,255 shares of Common Stock 

 

	4.	Sanders Opportunity Fund (Institutional), L.P. 

 656,306 shares of Common Stock

  

	5.	Don Sanders 

 340,555 shares of Common Stock 

 

	6.	Kathy Sanders 

 170,277 shares of Common Stock 

 

	7.	Sanders 1998 Children’s Trust 

 170,277 shares of Common Stock 

 

	8.	Tanya Drury 

 42,569 shares of Common Stock 

 

	9.	George Ball 

 42,569 shares of Common Stock 

 

	10.	Don Weir 

 42,569 shares of Common Stock 

 

	11.	Ben Morris 

 42,569 shares of Common Stock 

 

	12.	Edward Flynn 

 13,282 shares of Series H 

46,326 shares of Series I 

1,331,420 shares of Common Stock 

  
 16 

	13.	Mark A. Logomasini & Associates Inc. SEP Fund 

 62,156 shares of Series I

  

	14.	Mark Logomasini 

 11,173 Shares of Series H 

 

	15.	David Tierney 

 78,400 shares of Common Stock 

 

	16.	Ralph Makar 

 78,400 shares of Common Stock 

 

	17.	Richard Stout 

 11,700 shares of Common Stock 

 

	18.	Christine Farrell 

 11,700 shares of Common Stock 

 

	19.	Richard Richieri 

 5,395 shares of Series I 

 

	20.	Albert Hansen 

 1,079 shares of Series I 

  
 17

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00230-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00230-of-00352.parquet"}]]